December 2015

Favourable feedback from the European Medicines Agency

Galen received a positive evaluation from the European Medicines Agency (EMA) on the methodology they are using to develop a new outcome measure for patients with neurofibromatosis type 1 with associated plexiforms. The study is funded by the US charity NTAP (Neurofibromatosis Therapeutic Acceleration Program). It is anticipated that the scale will be used in clinical trials to determine whether interventions improve quality of life.